SCHEMBL6496541

SCHEMBL6496541

COc1cccc(CN2CCN(c3ccc(NC(=O)C4=C(c5ccc(C(F)(F)F)cc5)CCCC4)cc3)CC2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.57
LMNA P02545 5/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
HSD17B10 Q99714 3/20 0.55
KDM4E B2RXH2 2/20 0.55
TP53 P04637 2/20 0.55
TSHR P16473 2/20 0.55
SRPK1 Q96SB4 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
KMT2A Q03164 1/20 0.51
ALDH1A1 P00352 3/20 0.49
KDM4C Q9H3R0 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
HIF1A Q16665 1/20 0.49
EPAS1 Q99814 1/20 0.49
CCNC P24863 1/20 0.48
CDK8 P49336 1/20 0.48
NPSR1 Q6W5P4 1/20 0.47
USP2 O75604 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490947 0.90 HIF1A (0.51) MAPTLMNASMN1; SMN2KDM4EL3MBTL1
SCHEMBL6500838 0.89 MAPT (0.56) MAPTLMNASMN1; SMN2HSD17B10KDM4E
SCHEMBL6490911 0.88 HIF1A (0.53) MAPTLMNASMN1; SMN2KDM4EL3MBTL1
SCHEMBL6490805 0.88 HIF1A (0.64) MAPTLMNASMN1; SMN2HSD17B10KDM4E
SCHEMBL6488692 0.86 SLC2A1 (0.52) MAPTLMNASMN1; SMN2KDM4EALDH1A1
SCHEMBL6498359 0.85 TNF (0.49) MAPTSRPK1NR1H4
SCHEMBL6492808 0.80 HIF1A (0.46) KDM4ESRPK1ALDH1A1KDM4CTDP1
SCHEMBL6490755 0.80 CA1 (0.51) MAPTLMNAKDM4ETP53ALDH1A1
SCHEMBL6499822 0.79 MAPKAPK2 (0.46) MAPTKDM4EALDH1A1KDM4CTDP1
SCHEMBL6501481 0.79 CA1 (0.52) MAPTLMNAKDM4ETP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 MAPT 4202/4885LMNA 629/4885SMN1; SMN2 1921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.